Polyethylene glycol 3350; potassium chloride; sodium bicarbonate; sodium chloride - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for polyethylene glycol 3350; potassium chloride; sodium bicarbonate; sodium chloride and what is the scope of patent protection?
Polyethylene glycol 3350; potassium chloride; sodium bicarbonate; sodium chloride
is the generic ingredient in nineteen branded drugs marketed by L Perrigo Co, Azurity, Extrovis, Novel Labs Inc, Solis Pharms, Strides Pharma, Aurobindo Pharma Usa, Paddock Llc, Hospira, Strides Pharma Intl, Vintage Pharms, Dynapharm, E Z Em, Goldline, and Sandoz, and is included in twenty-two NDAs. Additional information is available in the individual branded drug profile pages.Five suppliers are listed for this compound.
Summary for polyethylene glycol 3350; potassium chloride; sodium bicarbonate; sodium chloride
| US Patents: | 0 |
| Tradenames: | 19 |
| Applicants: | 15 |
| NDAs: | 22 |
| Finished Product Suppliers / Packagers: | 5 |
| Clinical Trials: | 1 |
| DailyMed Link: | polyethylene glycol 3350; potassium chloride; sodium bicarbonate; sodium chloride at DailyMed |
Recent Clinical Trials for polyethylene glycol 3350; potassium chloride; sodium bicarbonate; sodium chloride
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Temple University | Phase 4 |
Pharmacology for polyethylene glycol 3350; potassium chloride; sodium bicarbonate; sodium chloride
| Drug Class | Osmotic Laxative Potassium Salt |
| Mechanism of Action | Osmotic Activity Alkalinizing Activity |
| Physiological Effect | Increased Large Intestinal Motility Inhibition Large Intestine Fluid/Electrolyte Absorption Stimulation Large Intestine Fluid/Electrolyte Secretion |
Anatomical Therapeutic Chemical (ATC) Classes for polyethylene glycol 3350; potassium chloride; sodium bicarbonate; sodium chloride
US Patents and Regulatory Information for polyethylene glycol 3350; potassium chloride; sodium bicarbonate; sodium chloride
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospira | OCL | polyethylene glycol 3350; potassium chloride; sodium bicarbonate; sodium chloride; sodium sulfate | SOLUTION;ORAL | 019284-001 | Apr 30, 1986 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Sandoz | PEG-LYTE | polyethylene glycol 3350; potassium chloride; sodium bicarbonate; sodium chloride; sodium sulfate anhydrous | FOR SUSPENSION;ORAL | 073098-001 | Aug 31, 1993 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Aurobindo Pharma Usa | TRILYTE | polyethylene glycol 3350; potassium chloride; sodium bicarbonate; sodium chloride | FOR SOLUTION;ORAL | 076491-001 | Feb 5, 2004 | AA | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Strides Pharma Intl | COLYTE-FLAVORED | polyethylene glycol 3350; potassium chloride; sodium bicarbonate; sodium chloride; sodium sulfate anhydrous | FOR SOLUTION;ORAL | 018983-009 | Nov 14, 1991 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch